WEREWOLF THERAPEUTICS INC (HOWL) Stock Price, Quote, News and Overview
NASDAQ:HOWL - Nasdaq - US95075A1079 - Common Stock - Currency: USD
HOWL Quote, Performance and Key Statistics
NASDAQ:HOWL (5/22/2025, 2:03:37 PM)
1.12
+0.04 (+3.7%)
The current stock price of HOWL is 1.12 USD. In the past month the price increased by 26.4%. In the past year, price decreased by -77.87%.
HOWL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.79 | 323.14B | ||
| AMGN | AMGEN INC | 13.07 | 145.91B | ||
| GILD | GILEAD SCIENCES INC | 13.8 | 133.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.13B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.45 | 64.34B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.72B | ||
| ARGX | ARGENX SE - ADR | 99.13 | 35.53B | ||
| ONC | BEIGENE LTD-ADR | 5.91 | 25.66B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.78B | ||
| NTRA | NATERA INC | N/A | 20.85B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.58B | ||
| BIIB | BIOGEN INC | 8 | 18.55B |
Related stock screener links
About HOWL
Company Profile
Werewolf Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The company is headquartered in Watertown, Massachusetts and currently employs 46 full-time employees. The company went IPO on 2021-04-30. The company is leveraging its PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s advanced clinical-stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules for the treatment of solid tumors. The company is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor. The company is advancing WTX-712, WTX-518, and WTX-921 through preclinical development.
Company Info
WEREWOLF THERAPEUTICS INC
200 Talcott Avenue, 2nd Floor
Watertown MASSACHUSETTS 02138 US
CEO: Daniel J. Hicklin
Employees: 45
Phone: 16179520555
WEREWOLF THERAPEUTICS INC / HOWL FAQ
What is the stock price of WEREWOLF THERAPEUTICS INC today?
The current stock price of HOWL is 1.12 USD. The price increased by 3.7% in the last trading session.
What is the ticker symbol for WEREWOLF THERAPEUTICS INC stock?
The exchange symbol of WEREWOLF THERAPEUTICS INC is HOWL and it is listed on the Nasdaq exchange.
On which exchange is HOWL stock listed?
HOWL stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for WEREWOLF THERAPEUTICS INC stock?
12 analysts have analysed HOWL and the average price target is 10.4 USD. This implies a price increase of 828.93% is expected in the next year compared to the current price of 1.12. Check the WEREWOLF THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is WEREWOLF THERAPEUTICS INC worth?
WEREWOLF THERAPEUTICS INC (HOWL) has a market capitalization of 50.25M USD. This makes HOWL a Micro Cap stock.
How many employees does WEREWOLF THERAPEUTICS INC have?
WEREWOLF THERAPEUTICS INC (HOWL) currently has 45 employees.
What are the support and resistance levels for WEREWOLF THERAPEUTICS INC (HOWL) stock?
WEREWOLF THERAPEUTICS INC (HOWL) has a support level at 0.86 and a resistance level at 1.12. Check the full technical report for a detailed analysis of HOWL support and resistance levels.
Is WEREWOLF THERAPEUTICS INC (HOWL) expected to grow?
The Revenue of WEREWOLF THERAPEUTICS INC (HOWL) is expected to decline by -46.79% in the next year. Check the estimates tab for more information on the HOWL EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy WEREWOLF THERAPEUTICS INC (HOWL) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of HOWL, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of HOWL, evaluating the profitability, health, valuation and growth aspects
- WEREWOLF THERAPEUTICS INC (HOWL) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- WEREWOLF THERAPEUTICS INC (HOWL) Sales and EPS estimates to see what analysts future expectations are.
- WEREWOLF THERAPEUTICS INC (HOWL) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- WEREWOLF THERAPEUTICS INC (HOWL) Insider and Institutional Ownership to learn about the owners and their transactions.
- WEREWOLF THERAPEUTICS INC (HOWL) Stock Chart to make your own analysis
- WEREWOLF THERAPEUTICS INC (HOWL) Latest news and press-releases to stay up to date.
Does WEREWOLF THERAPEUTICS INC (HOWL) stock pay dividends?
HOWL does not pay a dividend.
What is the Price/Earnings (PE) ratio of WEREWOLF THERAPEUTICS INC (HOWL)?
WEREWOLF THERAPEUTICS INC (HOWL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.64).
What is the Short Interest ratio of WEREWOLF THERAPEUTICS INC (HOWL) stock?
The outstanding short interest for WEREWOLF THERAPEUTICS INC (HOWL) is 5.1% of its float. Check the ownership tab for more information on the HOWL short interest.
HOWL Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to HOWL. When comparing the yearly performance of all stocks, HOWL is a bad performer in the overall market: 94.03% of all stocks are doing better.
HOWL Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to HOWL. HOWL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
HOWL Financial Highlights
Over the last trailing twelve months HOWL reported a non-GAAP Earnings per Share(EPS) of -1.64. The EPS decreased by -50.46% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -67.52% | ||
| ROE | -126.36% | ||
| Debt/Equity | 0.46 |
HOWL Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 88% to HOWL. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of -12.74% and a revenue growth -46.79% for HOWL